Professor Chris Gale discusses a consensus statement on strategies for the identification and management of cardiopulmonary ...

Generated $166.8 million in 1Q 2025 revenues, including $149.9 million in U.S. net product sales <li /> SYFOVRE® (pegcetacop ...

Generated $166.8 million in 1Q 2025 revenues, including $149.9 million in U.S. net product salesSYFOVRE® (pegcetacoplan injection) injection demand grew 4% quarter-over-quarter, with U.S. net product ...

in adults with paroxysmal nocturnal haemoglobinuria (PNH), a debilitating ultra-rare blood disorder in which the body's complement system destroys red blood cells. The study enrolled patients who ...

WALTHAM, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced its first quarter 2025 financial results and business highlights. "In the first quarter, ...

The US FDA has approved the first biosimilar version of AstraZeneca/Alexion’s Soliris therapy for paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic ...

Taft had two signs of OSA: excessive daytime somnolence and snoring. He may also have been polycythemic: his face was described as "ruddy" [13(p161)] and "florid." [6(p159),9,39(p28)] Systemic ...

Table 2. Recommendations for the use of erythropoiesis-stimulating agents in patients with nonhematological malignancies. Organization Anemia related to chemotherapy Untreated patients Patients ...